OPTINOSE INC (OPTN) Stock Price, Quote, News and Overview
NASDAQ:OPTN - Nasdaq - US68404V1008 - Common Stock - Currency: USD
OPTN Quote, Performance and Key Statistics
OPTINOSE INC
NASDAQ:OPTN (2/10/2025, 8:16:17 PM)
5.7
-0.11 (-1.89%)
The current stock price of OPTN is 5.7 USD. In the past month the price increased by 7.65%. In the past year, price decreased by -72.16%.
OPTN Latest News and Analysis
Monday's pre-market session: top gainers and losers
Discover the top movers in Monday's pre-market session and stay informed about market dynamics.
Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20%
Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20%...
Optinose Announces 1-for-15 Reverse Stock Split
Optinose Announces 1-for-15 Reverse Stock Split
YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and...
OPTN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 66.84 | 824.85B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 26.55 | 372.57B | ||
| JNJ | JOHNSON & JOHNSON | 15.44 | 371.35B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.13 | 225.33B | ||
| MRK | MERCK & CO. INC. | 11.31 | 218.56B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.63 | 213.62B | ||
| PFE | PFIZER INC | 8.32 | 146.61B | ||
| SNY | SANOFI-ADR | 13.45 | 133.58B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.71 | 112.62B | ||
| ZTS | ZOETIS INC | 29.85 | 77.56B | ||
| GSK | GSK PLC-SPON ADR | 7.91 | 74.41B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 30.52 | 42.58B |
Related stock screener links
About OPTN
Company Profile
OptiNose, Inc. operates as a pharmaceutical company. The company is headquartered in Yardley, Pennsylvania and currently employs 132 full-time employees. The company went IPO on 2017-10-13. The firm's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. The firm has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.
Company Info
OPTINOSE INC
777 Township Line Road, Suite 300
Yardley PENNSYLVANIA 19067 US
CEO: Peter K. Miller
Employees: 132
Company Website: https://www.optinose.com/
Investor Relations: http://ir.optinose.com/
Phone: 12673643500
OPTN FAQ
What is the stock price of OPTN?
The current stock price of OPTN is 5.7 USD.
What is the symbol for OPTINOSE INC stock?
The exchange symbol of OPTINOSE INC is OPTN and it is listed on the Nasdaq exchange.
On which exchange is OPTN stock listed?
OPTN stock is listed on the Nasdaq exchange.
Is OPTN a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for OPTN, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of OPTN.
Does OPTN stock pay dividends?
OPTN does not pay a dividend.
What is the Price/Earnings (PE) ratio of OPTN?
OPTN does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.64).
OPTN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to OPTN. When comparing the yearly performance of all stocks, OPTN is a bad performer in the overall market: 94.76% of all stocks are doing better.
OPTN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OPTN. Both the profitability and financial health of OPTN have multiple concerns.
OPTN Financial Highlights
Over the last trailing twelve months OPTN reported a non-GAAP Earnings per Share(EPS) of -2.64. The EPS increased by -560% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.51% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OPTN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to OPTN. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -872.19% and a revenue growth 12.22% for OPTN